Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Association between Timing and Duration of Adjuvant Chemotherapy and Colorectal Cancer Survival in Korea, 2011-2014: A Nationwide Study based on the Health Insurance Review and Assessment Service Database

Full metadata record
DC Field Value Language
dc.contributor.authorChoi, Jin Hwa-
dc.contributor.authorLee, Ji Sung-
dc.contributor.authorBaek, Sun Kyung-
dc.contributor.authorKim, Jong Gwang-
dc.contributor.authorKim, Tae Won-
dc.contributor.authorSohn, Seung Kook-
dc.contributor.authorKang, Mi Yeon-
dc.contributor.authorLee, Sang-Cheol-
dc.contributor.authorHwang, In Gyu-
dc.date.accessioned2022-06-02T00:40:06Z-
dc.date.available2022-06-02T00:40:06Z-
dc.date.issued2022-05-
dc.identifier.issn1837-9664-
dc.identifier.urihttps://scholarworks.bwise.kr/cau/handle/2019.sw.cau/58188-
dc.description.abstractBackground: Population-based analyses of the treatment outcomes of colorectal cancer (CRC) in Asian countries are limited. Therefore, we conducted a nationwide study to assess the relationship between the timing and duration of adjuvant chemotherapy (AC) and survival in patients with CRC in South Korea. Methods: Data on AC from the Health Insurance Review and Assessment Service Database (HIRA) were analyzed, and the survival of patients who underwent curative-intent surgical resection for CRC between 2011 and 2014 was investigated. Results: From the HIRA data, 45,992 patients with stage II-III CRC were identified. Chemotherapy regimens were administered as follows: 10,640 (23.3%) received 5-fluorouracil and leucovorin/capecitabine (FL/CAP), 13,083 (28.7%) received FUCAP plus oxaliplatin (FOLFOX/CAPDX), 299 (0.7%) received uracil and tegafur/doxifluridine (UFT/D), and 21,570 (47.3%) underwent surgery alone. Patients who did not receive AC had worse survival than those who received AC in both the colon and rectum groups (HR, 1.96, 95% CI, 1.85-2.07 and HR, 2.18, 95% CI, 2.01-2.37, respectively). Regarding patients with stage II-III CRC, AC initiation >= 2 months after surgery was associated with a significant decrease in overall survival (OS) (FUCAP: HR, 1.82; 95% CI, 1.53-2.17 and FOLFOX/CAPDX: HR, 2.92; 95% CI, 2.47-3.45); however, the effects of UFT/D regimens were not statistically significant. For patients with stage II-III colon cancer, AC <3 months had lower OS (FL/CAP: HR, 3.72, 95% CI, 2.80-4.94; FOLFOX/CAPDX: HR, 2.15, 95% CI, 1.87-2.47; and UFT/D: HR, 1.74, 95% CI, 0.56-5.41). In terms of patients with stage II-III rectal cancer, AC <3 months, regardless of chemotherapy regimens, had a significant lower survival (FUCAP: HR, 1.91, 95% CI, 1.66-2.20; FOLFOX/CAPDX: HR, 2.20, 95% CI, 1.75-2.77; and UFT/D: HR, 3.71, 95% CI, 1.45-9.44). Conclusions: Postoperative time to initiation and duration of AC were associated with survival. Based on our results, initiating AC within 2 months after surgery and administering AC for >3 months can potentially have an OS benefit in patients with stage II-III CRC.-
dc.format.extent7-
dc.language영어-
dc.language.isoENG-
dc.publisherIVYSPRING INT PUBL-
dc.titleAssociation between Timing and Duration of Adjuvant Chemotherapy and Colorectal Cancer Survival in Korea, 2011-2014: A Nationwide Study based on the Health Insurance Review and Assessment Service Database-
dc.typeArticle-
dc.identifier.doi10.7150/jca.71141-
dc.identifier.bibliographicCitationJOURNAL OF CANCER, v.13, no.7, pp 2440 - 2446-
dc.description.isOpenAccessY-
dc.identifier.wosid000795768400008-
dc.identifier.scopusid2-s2.0-85130183347-
dc.citation.endPage2446-
dc.citation.number7-
dc.citation.startPage2440-
dc.citation.titleJOURNAL OF CANCER-
dc.citation.volume13-
dc.type.docTypeArticle-
dc.publisher.location호주-
dc.subject.keywordAuthorcolorectal cancer-
dc.subject.keywordAuthoradjuvant chemotherapy-
dc.subject.keywordAuthortiming-
dc.subject.keywordAuthorduration-
dc.subject.keywordPlusIII COLON-CANCER-
dc.subject.keywordPlusSTAGE-II-
dc.subject.keywordPlusFLUOROURACIL-
dc.subject.keywordPlusLEUCOVORIN-
dc.subject.keywordPlusTHERAPY-
dc.subject.keywordPlusOXALIPLATIN-
dc.subject.keywordPlusINITIATION-
dc.subject.keywordPlusSURGERY-
dc.relation.journalResearchAreaOncology-
dc.relation.journalWebOfScienceCategoryOncology-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
Files in This Item
Appears in
Collections
College of Medicine > College of Medicine > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Hwang, In Gyu photo

Hwang, In Gyu
의과대학 (의학부(임상-서울))
Read more

Altmetrics

Total Views & Downloads

BROWSE